Associated Papers
CEBPA double mutations associated with ABO antigen weakness in hematologic diseases.
Choi SJ et al.
Blood Advances, 2024
38359363 (PubMed )
Supplement: BLOODA_ADV-2023-011572-mmc1.xlsx › Supplementary_Table_5
Germline pathogenic variants in transcription factors predisposing to pediatric acute myeloid leukemia: results from the French ELAM02 trial.
Fenwarth L et al.
Haematologica, 2021
32554555 (PubMed )
Supplement: 2020_248872_FENWARTH_SUPPL.pdf
Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer.
Yun MR et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2020
Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD.
Wen XM et al.
International Journal of Clinical and Experimental Pathology, 2014
CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic risk.
Park SH et al.
Leukemia Research, 2013
Select a paper to view details